Industry urged to coordinate on health insurance review: Sclavos


stethoscope on $20 note

When a patient presents at a pharmacy with a private prescription not covered by the PBS, most patients are disappointed by the benefits they receive under their ancillary benefits private health insurance cover, and an alarming number don’t even know they have pharmacy extras (ancillary) cover, says Kos Sclavos.

Sinapse Pty Ltd runs professional pharmacy programs for private prescription medicines.

With up to 90 cents from each dollar spent on premiums paid to healthcare providers, pharmacy extras coverage is cross subsidising other health services, says Senior Health Strategist at Sinapse, Kos Sclavos.

Health Minister Sussan Ley has flagged abolishing the 30% rebate on ancillary cover that ensures services such as pharmaceuticals, dental, physio and optical care leaving the strong indication that government rebates with only cover hospital costs, he says.

More than $17 billion a year is spent covering private health treatments.

Sclavos, who has developed a number of patient support programs covering private prescription medicines, is calling for the pharmaceutical industry to have a coordinated approach to the latest Commonwealth Government heath review on private health insurance.

On Wednesday Health Minister Sussan Ley announced a public consultation to seek consumer feedback on private health insurance, he says.

Under the review the Department of Health will be conducting a series of roundtable discussions with key industry and consumer representatives.

Furthermore, Professor Graeme Samuel, the former Chairman of the Australian Competition and Consumer Commission, will be working with the Department of Health, to provide his technical expertise to these industry consultations.

“The pharmaceutical industry needs to come together to ensure we have a unified approach, and then approach the Government review with a formed policy to establish a viable private prescription market that does have Government support, including maintenance of the 30% rebate,” Sclavos says.

“We have a pharmacy extras coverage structure which varies greatly across health providers. We have a plethora of different models which are not understood by doctor or pharmacists leading to patients not being given appropriate advice.

“We have a private health insurance sector which does not give support tools to health professionals or patients to explain benefits. We have caps per prescription in terms of pay out benefits, and we have caps per year per specific ancillary benefit.

“Patients are not getting value for money.”

Sclavos says that Australia needs a viable private prescription funding model.

“The pharmaceutical industry in Australia needs a coordinated approach to the review of private health insurance to ensure a viable private prescription market is established in Australia,” he says.

“The sector should be seeking its own roundtable discussion with the chair Professor Graeme Samuel.

“In addition some health funds cover specific professional pharmacy programs that may assist with medication compliance and persistence. There is no national, widely available programs, which can be taught at the University sector and accessed through national education providers.

“Health funds should invest in professional pharmacy programs, within the ancillary pharmacy extras cover, that maximise medication compliance and concordance.

“It is in the interest of the health fund that this occur.”

 

Previous New atypical antipsychotic for schizophrenia has 'negligible' weight effect
Next Pharmacy cannibalises itself in search of retail edge

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.